Table 4 Impact of being high-risk opioid group and its severity on prospective costs
| Â | Total cost | Medical cost | Drug cost |
|---|---|---|---|
Crude cost change – binary indicator | |||
 Chronic users | 20,161** (18,775–21,547) | 10,925** (9637–12,213) | 9236** (8841–9632) |
 Concomitant users | 16,666** (15,893–17,439) | 11673** (10,954–12,392) | 4993** (4772–5214) |
 Opioid disorder | 15,026** (13,306–16,746) | 11,974** (10,377–13,571) | 3051** (2559–3544) |
Adjusted cost change (with covariates and weighting) – binary indicator | |||
 Chronic users | 6216** (5678–6754) | 281 (−123 to 795) | 5935** (5808–6063) |
 Concomitant users | 637* (134–1140) | -1036** (−1518 to −553) | 1673** (1546–1799) |
 Opioid disorder | 1558** (1039–2076) | 671** (161–1181) | 887** (809–964) |
Crude cost change (one level increase in severity) – severity level (0–3) | |||
 Severity of chronic users | 8845** (8205–9486) | 4523** (3928–5119) | 4322** (4139–4505) |
 Severity of concomitant users | 7343** (6987–7700) | 4959** (4628–5291) | 2384** (2282–2486) |
 Severity of opioid disorder | 6206** (5390–7022) | 4880** (4123–5637) | 1326** (1093–1560) |
Adjusted cost change (with covariates: one level increase in severity) – severity level (0–3) | |||
 Severity of chronic users | 3337** (2695–3978) | 263 (−344 to 869) | 3074** (2887–3261) |
 Severity of concomitant users | 1209** (840–1579) | 315 (−34 to 664) | 895** (787–1002) |
 Severity of opioid disorder | 1136* (206–2067) | 809 (−70 to 1688) | 328* (56–599) |